tetomilast (OPC-6535) / Otsuka  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tetomilast (OPC-6535) / Otsuka
NCT00064441: FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Completed
3
375
US
OPC-6535 Tablets (drug)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
05/06
05/06
NCT00064454 / 2005-003724-19: FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Completed
3
375
US
OPC-6535 Tablets (drug)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
07/06
07/06
NCT00092508 / 2004-000611-25: CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Completed
3
1725
US
OPC-6535, Asacol®
Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
 
05/07
NCT00989573: A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease

Completed
2/3
191
Japan, RoW
Placebo, OPC-6535
Otsuka Pharmaceutical Co., Ltd.
Crohn's Disease
08/12
08/12

Download Options